单纯疱疹病毒疫苗价值概况
单纯疱疹病毒1型(HSV-1)和2型(HSV-2)感染呈慢性且高流行,HSV-2是生殖器溃疡病主要病因并增加HIV感染风险,HSV-1可致口眼疾病,两者均可致新生儿疱疹和神经系统疾病。鉴于现有防控措施有限,疫苗接种是减少HSV相关疾病负担最高效的策略,包括预防性疫苗(针对易感青少年)和治疗性疫苗(针对有症状生殖器HSV-2感染者)。本文由多领域专家基于公开信息制定疫苗价值概况,评估在研疫苗的潜在公共卫生、经济和社会价值,并识别研究知识空白。
要点
- HSV-1和HSV-2感染呈慢性且高流行,造成全球显著疾病负担。
- HSV-2是生殖器溃疡病主要病因,并增加HIV感染风险。
- 疫苗策略包括预防性疫苗(易感青少年)和治疗性疫苗(有症状生殖器HSV-2感染者)。
核心结论
- 鉴于HSV-1和HSV-2感染的普遍性和现有防控措施有限,疫苗接种是减少HSV感染相关全球疾病负担最高效的策略。
研究设计与样本
- 本疫苗价值概况由来自学术界、非营利组织、政府机构和多边组织的主题专家制定,仅使用现有和公开可用的信息。
主要发现
- HSV-2经性传播,是生殖器溃疡病的主要病因,并增加HIV感染风险,助推HIV流行。
- HSV-1通常通过非性接触在儿童期获得,可致口腔和眼部疾病,也可经性传播引起生殖器溃疡病。
- HSV-1和HSV-2均可引起新生儿疱疹和神经系统疾病。
- 疫苗策略包括预防性疫苗接种(可能给予青少年)和治疗性疫苗接种(给予有症状的生殖器HSV-2感染者)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines. This 'Vaccine Value Profile' (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
引用
- Johnston C, Scheele S, Bachmann L, et al. Vaccine value profile for herpes simplex virus. Vaccine. 2024. PMID: 39003018. doi:10.1016/j.vaccine.2024.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。